New remdesivir trial shows reduction in COVID-19 recovery time from 15 to 11 days; Benefits shown to decline as case severity increases with little effect on ventilated patients
UPMC using lottery to determine which patients receive remdesivir doses; Weighted to favor essential workers, economically distressed neighborhoods
Gilead donates additional 300k remdesivir doses to federal government, enough to treat 30 - 55k more patients
Gilead agrees to royalty-free generic reproduction of remdesivir for 127 countries through duration of pandemic; United States not included
HHS outlines plan for remdesivir distribution: drug supply will be given over to states, whose health departments will distribute to hospitals based on determinations of need
ICER suggests price of $4,500 per course for remdesivir as Gilead considers pricing strategy; Gilead donates 140,000 courses
